tbuckley/cabot-search huggingface dataset:
Abstract 2958: The novel protein kinase STK17A is a direct p53 target gene that mediates response to genotoxic and nutritional stress in a cancer cell context-dependent manner
Authors: Pingping Mao, Mary Jardine, Lynn Niemaszyk, Jessica Haghkerdar, Eric Yang, Esty G. yanco, Damayanti Desai, Maroun Beyrouthy, Joanna S. Kerley-Hamilton, Sarah J. Freemantle, Michael J. Spinella
Journal: Cancer Research (2012)

Abstract STK17A (DRAK1) is a largely uncharacterized serine/threonine kinase that belongs to the death-associated protein kinase family. Prior microarray studies demonstrated that STK17A is induced with cisplatin in testicular cancer-derived human embryonal carcinoma (EC) cells. We now demonstrate the STK17A in a novel p53 target gene that is induced by a variety of DNA damaging agents in a p53-dependent manner in a number of different cell contexts. A consensus and functional p53 response element was found upstream of the STK17A promoter and endogenous p53 was shown to bind to this site in a cisplatin-dependent manner. Knockdown of STK17A conferred resistance to cisplatin-induced growth suppression and apoptotic cell death in EC cells. This was associated with up-regulation of detoxifying and antioxidant genes and reduction in reactive oxygen species (ROS), whereas overexpression of STK17A increased ROS levels in EC cells. Interestingly, we found that STK17A is highly overexpressed in clinical glioblastoma (GBM) and cell lines compared to its expression in normal brain tissue and other cancers. High STK17A expression in GBM patients correlated with poor clinical outcome and decreased survival. STK17A knockdown in GBM cells decreased clonagenic cell growth, soft agar tumorigenicity, and survival in response to genotoxic and nutritional stress. Preliminary data will be presented implicating STK17A in the regulation of autophagy and the proximal autophagy component, ULK1. These findings indicate that STK17A may be added to a growing list of direct p53 target genes involved in autophagy that includes TIGAR, Sestrins, DAPK1 and DRAM and that by impacting autophagy STK17A may modulate response to genotoxic and nutritional stress in a cell context-depend manner. This study also suggests that STK17A is a potential novel prognostic maker and therapeutic target for GBM. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2958. doi:1538-7445.AM2012-2958
Cross sectional prevalence survey of idiopathic Parkinson's disease and parkinsonism in London
Authors: A Schrag, Y Ben-Shlomo, N P Quinn
Journal: BMJ (2000)

Only four prevalence studies of idiopathic Parkinson's disease in the United Kingdom have been published to date.These have been undertaken in the north of England or Scotland and span 30 years. [1]2][3][4] We report the prevalence of idiopathic Parkinson's disease and other parkinsonian syndromes in 1997 in the London area.
Diabetic Retinopathy in Blacks
Authors: Maurice F Rabb, Donald A Gagliano, Howard E Sweeney
Journal: Diabetes Care (1990)

Diabetic eye disease, particularly diabetic retinopathy, is the leading cause of new cases of legal blindness in people 20–74 yr of age in the United States. The prevalence and rate of diabetes in this age-group are higher in Blacks than in Whites. The rate of blindness from diabetic eye disease is also higher in Blacks than in Whites. Severe macular edema, the most frequent cause of decreased vision in diabetic retinopathy, appears to be more common in Blacks. Risk factors for developing macular edema include poorly controlled hypertension, hyperglycemia, and duration of disease. The higher prevalence of hypertension in Blacks may contribute to the increased severity of diabetic retinopathy. Further evaluation is necessary to determine the influence of race on the severity of diabetic retinopathy.
Diagnosis of Venous Thrombosis
Authors: Bruce H. Heckman
Journal: JAMA (1976)

<h3>To the Editor.—</h3> I think the title of the article, "Fallibility of the Clinical Diagnosis of Venous Thrombosis" (234: 605, 1975), is misleading. The article is very specific as to comparison of the Doppler technique to the venogram, but does not really talk about how often the clinician would have been inclined to treat the patient on the basis of bedside findings. From the statement that the diagnosis of acute venous thrombosis "was entertained," I infer that it was part of a differential diagnosis. In order to justify the title, an objective study of how often and how strongly the clinician believed he or she was dealing with acute thrombosis could have been designed. I certainly agree that there are many diseases that can mimic acute thrombosis, but this article did not accurately demonstrate how often a definite diagnosis was made and found to be in error.
New Instrument for Office Treatment of Cyst and Abscess of Bartholin's Gland
Authors: Buford Word
Journal: JAMA (1964)

AN INFLATABLE bulb-tipped catheter was devised to treat a cyst of Bartholin's gland. The successful use of this simple device is based on the age-old principle that a foreign body in a wound that prevents closure will result in the formation of an epithelized fistula or sinus tract. A new permanent orifice to a duct of Bartholin's gland is easily created by making a stab wound in the cyst in the region of the original orifice (Fig,<i>A</i>), inserting the catheter (Fig,<i>B</i>), and inflating the bulb with water (Fig,<i>C</i>). The catheter is left in place until epithelization of the new orifice is complete, which usually takes four to six weeks. In essence, an epithelized fistula is created between the cyst and the vaginal vestibule. After the catheter is removed, the cyst shrinks and becomes a duct again, and the resting gland resumes normal function. This technique has been
The Content of Their Character
Authors: Victor S. Sloan
Journal: Annals of Internal Medicine (2008)

On Being a Doctor15 July 2008The Content of Their CharacterVictor S. Sloan, MDVictor S. Sloan, MDFrom Robert Wood Johnson Medical School, New Brunswick, NJ 08901.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-149-2-200807150-00012 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail 1992: an urban emergency room, the midnight to 8 a.m. shift. It was the middle of my second year in medicine residency. There was a basket full of yellow-dot charts. These were the patients who always seemed to come in at 3 a.m. with colds, back pain for 6 months, and other minor problems. Our attending was Dr. Johnson. Not much older than most of the residents, he always looked like he had slept in his clothes (often he had) and usually he had 2 days' worth of facial hair. He was efficient, if a little rough around the edges, ...References1. U.S. Department of Health and Human Services. National Healthcare Quality Report, 2005. Rockville, MD: Agency for Healthcare Research and Quality; 2005. Accessed at www.ahrq.gov/qual/nhqr05/nhqr05.htm on 15 August 2007. Google Scholar2. American College of Physicians. Racial and ethnic disparities in health care: a position paper of the American College of Physicians. Ann Intern Med. 2004;141:226-32. [PMID: 15289223] LinkGoogle Scholar Author, Article, and Disclosure InformationAuthors: Victor S. Sloan, MDAffiliations: From Robert Wood Johnson Medical School, New Brunswick, NJ 08901.Note: All names have been changed.Corresponding Author: Victor S. Sloan, MD, Celgene Corporation, 106 Allen Road, Suite 402, Basking Ridge, NJ 07920; e-mail, [email protected]com. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoDo Race and Ethnicity Play a Substantial Role in the Quality of Care That Patients Receive in the U.S. Health Care System? Steven M. Hegedus Do Race and Ethnicity Play a Substantial Role in the Quality of Care That Patients Receive in the U.S. Health Care System? Victor S. Sloan Metrics Cited byHealthcare Providers’ Responses to Narrative Communication About Racial Healthcare DisparitiesWhat Causes Racial Health Care Disparities? A Mixed-Methods Study Reveals Variability in How Health Care Providers Perceive Causal AttributionsDo Race and Ethnicity Play a Substantial Role in the Quality of Care That Patients Receive in the U.S. Health Care System?Steven M. Hegedus, MD 15 July 2008Volume 149, Issue 2Page: 142-143KeywordsEmergency departmentHealth careHealth care qualityHipHispanic peopleIntensive care unitsOrthopedicsPulmonary hypertensionRacial and ethnic issuesSurgery ePublished: 15 July 2008 Issue Published: 15 July 2008 Copyright & PermissionsCopyright © 2008 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Plan B Overruled
Authors: Bridget M. Kuehn
Journal: JAMA (2012)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ceramide 2 (<i>N</i>-acetyl sphingosine) is associated with reduction in Bcl-2 protein levels by Western blotting and with apoptosis in cultured human keratinocytes
Authors: A. Di Nardo, L. Benassi, C. Magnoni, A. Cossarizza, S. Seidenari, A. Giannetti
Journal: British Journal of Dermatology (2000)

Ceramides produced by sphingomyelin hydrolysis activate a cycle that is followed by three different major cellular responses: downregulation of cell proliferation, induction of cell differentiation and apoptosis. In the skin, the generation of intracellular ceramide may also provide a link between an extracellular signal and the induction of the apoptosis programme for the elimination of damaged cells.We investigated the effect of ceramides capable of entering cells on cultured keratinocytes.Human keratinocytes from neonatal skin were cultured in serum-free medium with or without increasing concentrations of ceramide 2 (CER-2; N-acetyl sphingosine) (5, 10, 20 and 40 micromol L-1). Proliferative effects were studied either by cell counts or by 3H-thymidine incorporation and flow cytometric analysis. Apoptosis was studied by TUNEL staining and Western blot analysis of Bcl-2 protein.Cell counts and DNA synthesis were reduced in a dose-dependent manner following CER-2 treatment. TUNEL staining showed CER-2-induced apoptosis at 48, 72 and 96 h. Western blot analysis showed that CER-2 induces downregulation of Bcl-2 at 24-96 h.These results demonstrate that CER-2 inhibits cell proliferation and induces apoptosis, possibly via a Bcl-2-dependent mechanism.
Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes.
Authors: P Raskin, L Jovanovic, S Berger, S Schwartz, V Woo, R Ratner
Journal: Diabetes Care (2000)

OBJECTIVE: This multicenter open-label clinical trial compared the efficacy and safety of repaglinide/troglitazone combination therapy, repaglinide monotherapy, and troglitazone monotherapy in type 2 diabetes that had been inadequately controlled by sulfonylureas, acarbose, or metformin alone. RESEARCH DESIGN AND METHODS: Patients with type 2 diabetes (n = 256) who had inadequate glycemic control (HbA1c &amp;gt; or =7.0%) during previous monotherapy were randomly assigned to receive repaglinide (0.5-4.0 mg at meals), troglitazone (200-600 mg once daily), or a combination of repaglinide (1-4 mg at meals) and troglitazone (200-600 mg once daily). After a 4-6 week washout period, the trial assessed 22 weeks of treatment: 3 weeks (weeks 0-2) of forced titration, 11 weeks of fixed-dose treatment (weeks 3-13), and 8 weeks (weeks 14-21) of titration to maximum dose. Changes in HbA1c and fasting plasma glucose (FPG) values were measured. RESULTS: The combination therapy showed a significant reduction in mean HbA1c values (-1.7%) that was greater than with either type of monotherapy Repaglinide monotherapy resulted in a reduction of HbA1c values that was significantly greater than troglitazone (-0.8 vs. -0.4%) (P &amp;lt; 0.05). Combination therapy was more effective in reducing FPG values (-80 mg/dl) than either repaglinide (-43 mg/dl) or troglitazone (-46 mg/dl) monotherapies. Adverse events were similar in all groups. CONCLUSIONS: Combination therapy with repaglinide and troglitazone leads to better glycemic control than monotherapy with either agent alone. Repaglinide monotherapy was more effective in lowering HbA1c levels than troglitazone monotherapy Repaglinide/troglitazone combination therapy was effective and did not show unexpected adverse events.
974-41 Combination of Myocardial Contrast Echocardiography and Dobutamine Echocardlography In the Assessment of Myocardial Viability
Authors: Mario F. Meza, Marc A. Kates, R. Wayne Barbee, Susan Revall, Sameh Mobarek, Joseph P. Murgo, Jorge Cheirif
Journal: Journal of the American College of Cardiology (1995)
Bacteria and the skin: clinical practice and therapy update
Authors: None Thestrup-Pedersen
Journal: British Journal of Dermatology (1998)

Any doctor using antibiotics should be aware of the increasing worldwide problem with multiresistent bacteria, with the majority of hospital-based infections in some countries being caused by these bacteria. Proper use of antibiotics is therefore mandatory for any physician, including for dermatologists, who treat bacterial infections of the skin. Detailed knowledge is needed of when to use topical versus systemic antibiotics, and for how long such treatments should be given. Besides the clinical symptoms of bacterial infections and treatment guidelines, an increased awareness has focused on the possible importance of bacterial toxins, including superantigens, and their contribution to skin inflammation. Rare syndromes such as Kawasaki's syndrome, toxic epidermal necrolysis or staphylococcal scalded skin syndrome, are well-known diseases elicited by specific bacterial toxins. But many observations give indirect support to the notion that bacteriae can augment the immune inflammation seen in common and important diseases such as psoriasis and atopic dermatitis. This supplement provides up-to-date information about skin bacteriology, information on the possible importance of superantigens for chronic skin diseases, and practical guidelines for the use of both topical and systemic antibiotic therapy, together with a review of the dangers following improper use. This information is important for all doctors, including dermatologists.
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Authors: Dennis M. Black, Pierre D. Delmas, Richard Eastell, Ian R. Reid, Steven Boonen, Jane A. Cauley, Felicia Cosman, Péter Lakatos, Ping Chung Leung, Zulema Man, Carlos Mautalen, Peter Mesenbrink, Huilin Hu, John Caminis, Karen Tong, Theresa Rosario-Jansen, Joel Krasnow, Trisha F. Hue, Deborah Sellmeyer, Erik Fink Eriksen, Steven R. Cummings
Journal: New England Journal of Medicine (2007)

A single infusion of intravenous zoledronic acid decreases bone turnover and improves bone density at 12 months in postmenopausal women with osteoporosis. We assessed the effects of annual infusions of zoledronic acid on fracture risk during a 3-year period.
Prevention of Chemotherapy-Induced Nausea and Emesis in Patients Responding Poorly to Previous Antiemetic Therapy
Authors: U. Bruntsch, S. Drechsler, E. Hiller, W. Eiermann, A.H. Tulusan, M. Bühner, R. Hartenstein, H.J. Koenig, W.M. Gallmeier
Journal: Drugs (1992)
The Truth About Breast Implants
Authors: J M Dixon
Journal: BMJ (1994)

Randolph H Guthrie, Doug Podolsky Wiley, £9.95, pp 208 ISBN 0-471-59418-0

Written by an American professor of plastic surgery and a news reporter, The Truth About Breast Implants is divided into easy to read short sections rather like a British tabloid newspaper. In fact much of the text would sit more comfortably there than in a supposedly scientific text. Guthrie is portrayed as a prophet leading women towards the promised land of saline filled implants while the book characterises the majority of plastic surgeons in the United States who support the continued use of silicone prostheses as money grabbing, unethical, poorly trained, and too unskilled …
Seropositivity in Dutch Crohn's disease patients against primed nude mouse lymph nodes, and the difference with lymphocytotoxic antibodies.
Authors: A S Pena, I Kuiper, H C Walvoort, H W Verspaget, I T Weterman, E J Ruitenberg, K M Das
Journal: Gut (1986)

Sera from patients with Crohn9s disease have been reported to show positive immunofluorescence with lymph nodes of nude mice primed with a filtrate of intestinal tissue affected with Crohn9s disease. An indirect immunofluorescence assay was used to test sera of 63 unrelated patients with Crohn9s disease, 21 with ulcerative colitis and 36 control subjects against lymph nodes of athymic nude (nu/nu) mice which had been injected with Crohn9s disease and ulcerative colitis intestinal tissue filtrates. Forty nine per cent of Crohn9s disease patients, 10% of ulcerative colitis patients and 3% of control sera reacted against lymph nodes of mice injected injected with ulcerative colitis intestinal tissue filtrates, 18% of Crohn9s disease sera were with intestinal tissue homogenate from Dutch Crohn9s patients. With the lymph nodes of mice injected with ulcerative colitis intestinal tissue filtrates, 18% of Crohn9s disease sera were positive, whereas all ulcerative colitis and control sera were negative. Lymph nodes from 18 of the 19 mice injected with Crohn9s disease tissue filtrates reacted with Crohn9s disease sera, whereas only three of these 19 mice reacted with ulcerative colitis sera. A comparative study, carried out in parallel with Crohn9s disease filtrate induced hyperplastic lymph nodes from the Bilthoven colony (W2) and from the New York colony (E671) using sera from 54 Crohn9s disease patients from Leiden, showed immunoreactivity with 44 and 57% of the Crohn9s disease sera against the two hyperplastic lymph nodes. Thirty six of the 54 Crohn9s disease sera (67%) reacted with either or both lymph nodes. Only 11% of the Crohn9s disease sera which were examined for immunofluorescence and lymphocytotoxic antibodies had lymphocytotoxic antibodies, whereas 40% and 46% of the same sera showed positive immunofluorescence against E671 and W2, respectively. Absorption studies indicated that lymphocytotoxic antibodies activity and the immunofluorescence against the primed nude mouse lymph node are mediated by different serum antibodies in Crohn9s disease. The reproducibility of the nude mouse immunofluorescence test system for a preferential immunoreactivity of Crohn9s disease sera against Crohn9s disease tissue primed murine lymph nodes has been confirmed by the present study. Further studies are necessary to find out whether crossreactive antigen(s) as recognised by some of the Crohn9s disease sera in mice injected with ulcerative colitis tissue filtrate is similar to the antigen(s) detected by Crohn9s disease sera in mice injected with Crohn9s disease tissue filtrates.
T-lymphoblastic Leukaemia: A Distinct Variant of Acute Leukaemia
Authors: D. Catovsky, J. M. Goldman, A. Okos, B. Frisch, D. A. G. Galton
Journal: BMJ (1974)

Two cases of acute lymphoblastic leukaemia (A.L.L.) of T-cell type are reported. Clinically they were characterized by very high peripheral blood blast cell counts at presentation, the early development of meningeal leukaemia, and relative resistance to treatment with combination chemotherapy. Leukaemic cells from both patients lacked all the B-cell markers investigated, but 60-65% of their cells formed rosettes with sheep red cells. Cytochemical and surface structure studies helped to define additional features of these cells and confirmed their T-cell nature.It seems that this variant of A.L.L. may not be uncommon and that it can be distinguished on clinical and immunological grounds from the usual type of A.L.L. which runs a less aggressive course and lacks B- or T-cell markers.
Coadministration of Telomerase Genetic Vaccine and a Novel TLR9 Agonist in Nonhuman Primates
Authors: Sridhar Dharmapuri, Daniela Peruzzi, Carmela Mennuni, Francesco Calvaruso, Saverio Giampaoli, Gaetano Barbato, Ekambar R Kandimalla, Sudhir Agrawal, Elisa Scarselli, Giuseppe Mesiti, Gennaro Ciliberto, Nicola La Monica, Luigi Aurisicchio
Journal: Molecular Therapy (2009)

The human telomerase reverse transcriptase (hTERT) is an attractive target for human cancer vaccination because its expression is reactivated in most human tumors. We have evaluated the ability of DNA electroporation (DNA-EP) and adenovirus serotype 6 (Ad6) to induce immune responses against hTERT in nonhuman primates (NHPs) (Macaca mulatta). Vaccination was effective in all treated animals, and the adaptive immune response remained detectable and long lasting without side effects. To further enhance the efficacy of the hTERT vaccine, we evaluated the combination of hTERT vaccine and a novel TLR9 agonist, referred to as immunomodulatory oligonucleotide (IMO). Monkeys were dosed weekly with IMO concurrently with the vaccine regimen and showed increases in cytokine secretion and activation of natural killer (NK) cells compared with the group that received vaccine alone. Using a peptide array, a specific profile of B-cell reactive epitopes was identified when hTERT vaccine was combined with IMO. The combination of IMO with hTERT genetic vaccine did not impact vaccine-induced TERT-specific cell-mediated immunity. Our results show that appropriate combination of a DNA-EP/Ad6-based cancer vaccine against hTERT with IMO induces multiple effects on innate and adaptive immune responses in NHPs.
Amyloid-related serum protein SAA in endotoxin-induced amyloidosis of the mink.
Authors: R F Anders, K Nordstoga, J B Natvig, G Husby
Journal: The Journal of Experimental Medicine (1976)

The concentration of the amyloid AA-related serum protein (SAA) was markedly increased after endotoxin injections in mink, mouse, rabbit, and man. It was particularly studied during the development of endotoxin-induced amyloidosis of the mink. Protein SAA was markedly elevated in all mink 24 h after the first endotoxin injection but had fallen to relatively low levels before the onset of amyloidosis at about 4 wk. These results are consistent with SAA being a circulating precursor of the amyloid fibril protein, AA. However, both proteins may be derived by proteolysis from a common precursor.